Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037089
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2002-05-14
Brief Title:
A Phase II Study of Paclitaxel UFT and Leucovorin in Patients With Metastatic Esophageal Cancer
Sponsor:
Edelman Martin MD
Organization:
Edelman Martin MD
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2005-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for patients with esophageal cancer that has spread to other areas The purpose of this study is to
1 Determine how well a combination of taxol UFT and leucovorin work in these patients
2 Determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs
3 Identify the side effects of this drug combination
1 Determine how well a combination of taxol UFT and leucovorin work in these patients
2 Determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs
3 Identify the side effects of this drug combination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UMCC 0110g | None | None | None |